Stratasys expands dental 3D printing in Europe with new deals

EDEN PRAIRIE, Minn. & REHOVOT, Israel - Stratasys Ltd. (NASDAQ: SSYS) announced today strategic partnerships with Nueva Galimplant in Spain and Gold Quadrat and Metaux Precieux in Germany. These collaborations aim to enhance the distribution of Stratasys’s dental 3D printing solutions, including the TrueDent™ digital dentures, across Europe, reflecting the company’s commitment to advancing digital dentistry.

The new alliances coincide with the upcoming IDS 2025 conference in Cologne, Germany, from March 25 to 29, where Stratasys will exhibit its multi-material 3D printing technologies. These solutions are designed to streamline dental lab workflows and increase production capabilities without additional labor, responding to the growing demand for digital dentistry. The company’s strategic focus appears to be paying off, with InvestingPro analysis showing a strong 37.5% stock price increase over the past six months.

Giacomo Anselmo, Stratasys’s Director of Dental Sales Commercial Leader EMEA, expressed enthusiasm for the partnerships, stating that the combined expertise and reputation of the new partners will extend the reach of Stratasys’s products to more customers in Europe.

A report by iData from February 2024 projects that the European market for denture solutions will grow from USD 2.19 billion in 2023 to USD 2.45 billion by 2028, indicating a rising demand for such technologies.

The partners have praised the collaboration, highlighting the innovation and quality Stratasys brings to the dental sector. They anticipate that the synergy will introduce cutting-edge technology and new opportunities. Stratasys’s PolyJet™ multi-material 3D printing technology, in particular, is expected to save time and costs for dental laboratories.

Stratasys is a global leader in additive manufacturing, offering 3D printing solutions across various industries, including aerospace, automotive, consumer products, and healthcare. The company’s 3D printers, polymer materials, software ecosystem, and parts on demand are designed to provide competitive advantages throughout the product value chain.

This expansion into the European dental market is part of Stratasys’s broader strategy to transform product design, manufacturing, and patient care with its innovative technologies. With annual revenue of $572 million and analysts expecting positive net income growth, Stratasys appears undervalued according to InvestingPro Fair Value analysis. The information for this article is based on a press release statement and InvestingPro data, where investors can access a comprehensive Pro Research Report with detailed analysis of Stratasys’s financial health and growth prospects.

In other recent news, Stratasys Ltd. reported its financial results for the fourth quarter of 2024, surpassing earnings per share (EPS) expectations with an actual EPS of $0.12 compared to the forecasted $0.10. Revenue for the quarter was $150.4 million, slightly exceeding the anticipated $149.88 million, though it marked a 3.8% decline year-over-year. The company’s full-year revenue was $572.5 million, down 8.8% from the previous year. Cantor Fitzgerald recently adjusted its outlook for Stratasys, lowering the price target from $15.00 to $14.00 while maintaining an Overweight rating. Analyst Troy Jensen noted a projected revenue growth of 0.9% for 2025, which is below the firm’s previous estimate of 2.5%. Stratasys has also filed its annual financial report for 2024, providing an overview of its financial performance. The company continues to emphasize innovation in 3D printing, focusing on smart and connected printers and advanced materials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.